Travere Therapeutics, Inc
Price
OptionsOpen the Sheet →FilingsNewest: 8-K, Director or officer changeSep 21 →InsidersNo open-market buys. 11 insiders sold $37.2M, 68 of 75 sales on a 10b5-1 plan.→HoldersJupiter Topco 12.0%BlackRock 8.5%FMR 7.5%→Financing →PeersClosest companies: RIGL, VRDN, MIRM→
From the filings
Figures
- Revenue
- $591.3Mlast 12 months
- Net income
- −$43.5Mlast 12 months
- Operating cash flow
- $39.6Mlast 12 months
- Cash and equivalents
- $117.7Mat the last balance sheet
- Shares outstanding
- 94.2M shareson issue